Surveillance of susceptibility patterns in 1297 Europeans and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobials agents

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 6, 2004, Pages 1039-1044

  Koeth, Laura M ^a   Good, Caryn E ^a   Appelbaum, Peter C ^b   Goldstein, Ellie J C ^c   Rodloff, Arne C ^d   Claros, Marina ^d   Dubreuil, Luc J ^e  

^a Laboratory Specialists Inc   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c R M ALDEN RESEARCH LABORATORY   (United States)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e ADRINORD   (France)

Author keywords

Amoxicillin clavulanic acid; Anaerobes; Susceptibility data

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CLINDAMYCIN; IMIPENEM; LEVOFLOXACIN; METRONIDAZOLE;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; CONTROLLED STUDY; DRUG POTENCY; EIKENELLA CORRODENS; EUROPE; FUSOBACTERIUM NUCLEATUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTOSTREPTOCOCCUS; PORPHYROMONAS; PREVOTELLA; SPECIES DIFFERENCE; UNITED STATES;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-INFECTIVE AGENTS; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; BETA-LACTAMASES; CARBON DIOXIDE; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; EUROPE; HUMANS; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE; QUALITY CONTROL; UNITED STATES;

EID: 3042552599     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh248     Document Type: Article

References (29)

1. Goldstein, E. J. C. (1996). Anaerobic bacteremia. Clinical Infectious Diseases 23, Suppl. 1, S97-101.
2. Feleke, G. & Forlenza, S. (1991). Anaerobic infections: the basics for primary care physicians. Postgraduate Medicine 89, 221-34.
3. Finegold, S. M. & Wexler, H. M. (1996). Present studies of therapy for anaerobic infections. Clinical Infectious Diseases 23, Suppl. 1, S9-14.
4. Sanders, C. V. & Aldridge, K. E. (1992). Current antimicrobial therapy of anaerobic infections. European Journal of Clinical Microbiology and Infectious Diseases 11, 999-1011.
5. Lee, K., Chong, Y., Jeong, S. H. et al. (1996). Emerging resistance of anaerobic bacteria to antimicrobial agents in South Korea. Clinical Infectious Diseases 23, Suppl. 1, S73-7.
6. Dubreuil, L., Breuil, J., Dublanchet, A. et al. (1992). Survey of the susceptibility patterns of Bacteroides fragilis group strains in France from 1977 to 1992. European Journal of Clinical Microbiology and Infectious Diseases 11, 1094-9.
7. Baquero, F. & Reig, M. (1992). Resistance of anaerobic bacteria to antimicrobial agents in Spain. European Journal of Clinical Microbiology and Infectious Diseases 11, 1016-20.
8. Finegold, S. M. (1997). Perspective on susceptibility testing of anaerobic bacteria. Clinical Infectious Diseases 25, Suppl. 2, S251-3.
9. Hardman, J. G. & Limbird, L. E. (1996). Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th edn. McGraw-Hill Professional, New York, NY, USA.
10. Nord, C. E. (1986). Mechanisms of β-lactam resistance in anaerobic bacteria. Review of Infectious Diseases 8, Suppl. 5, S543-8.
11. Appelbaum, P. C., Spangler, S. K. & Jacobs, M. R. (1990). β-Lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrobial Agents and Chemotherapy 34, 1546-50.
12. Rasmussen, B. A., Bush, K. & Tally, F. P. (1997). Antimicrobial resistance in anaerobes. Clinical Infectious Diseases 24, Suppl. 1, S110-20.
13. Jones, R. N. & the MYSTIC Advisory Board. (2000). Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility. Journal of Antimicrobial Chemotherapy 46, Topic T2, 1-8.
14. Stein, G. E., Schooley, S., Tyrrell, K. L. et al. (2003). Bactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum. Antimicrobial Agents and Chemotherapy 47, 1308-12.
15. Stein, G. E. & Goldstein, E. J. C. (2003). Review of the in vitro activity and potential clinical efficacy of levofloxacin in the treatment of anaerobic infections. Anaerobe 9, 75-81.
16. Goldstein, E. J. C., Citron, D. M., Warren, Y. et al. (1999). In vitro activity of gemifloxacin (SB 265805) against anaerobes. Antimicrobial Agents and Chemotherapy 43, 2231-5.
17. Ednie, L. M., Jacobs, M. R. & Appelbaum, P. C. (1998). Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms. Antimicrobial Agents and Chemotherapy 42, 2459-62.
18. Wexler, H. M., Molitoris, E. & Finegold, S. M. (1992). In vitro activities of three of the newer quinolones against anaerobic bacteria. Antimicrobial Agents and Chemotherapy 36, 239-43.
19. Aldridge, K. E. & Johnson, W. D. (1997). A comparison of susceptibility results of the Bacteroides fragilis group and other anaerobes by traditional MIC results and statistical methods. Journal of Antimicrobial Chemotherapy 39, 319-24.
20. National Committee for Clinical Laboratory Standards. (2001). Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria - Fifth Edition: Approved Standard M11-A5. NCCLS, Villanova, PA, USA.
21. Craig, W. A. (1998). Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clinical Infectious Diseases 26, 1-10.
22. Jacobs, M. R. (2001). Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clinical Microbiology and Infection 7, 589-96.
23. Jacobs, M. R., Spangler, S. K. & Appelbaum, P. C. (1990). Susceptibility of Bacteroides non-fragilis and fusobacteria to amoxicillin, amoxicillin/clavulanate, ticarcillin, ticarcillin/clavulanate, cefoxitin, imipenem and metronidazole. European Journal of Clinical Microbiology and Infectious Diseases 9, 417-21.
24. Jacobs, M. R., Spangler, S. K. & Appelbaum, P. C. (1990). β-Lactamase production, β-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres. Journal of Antimicrobial Chemotherapy 26, 361-70.
25. Cuchural, G. J., Tally, F. P., Jacobus, N. V. et al. (1990). Comparative activities of newer β-lactam agents against members of the Bacteroides fragilis group. Antimicrobial Agents and Chemotherapy 34, 479-80.
26. Sheikh, W., Pitkin, D. H. & Nadler, H. (1993). Antibacterial activity of meropenem and selected comparative agents against anaerobic bacteria at seven North American centers. Clinical Infectious Diseases 16, Suppl. 4, S361-6.
27. Betriu, C., Sanchez, A., Gomez, M. et al. (1999). In-vitro susceptibilities of species of the Bacteroides fragilis group to newer β-lactam agents. Journal of Antimicrobial Chemotherapy 43, 133-6.
28. Dubreuil, L., Singer, E., Odou, M. F. et al. (1999). Antianaerobic activity of grepafloxacin compared with ofloxacin, ciprofloxacin, clindamycin, metronidazole and 5 β-lactams. Drugs 58, Suppl. 2, 110-2.
29. Edlund, C., Sabouri, S. & Nord, C. E. (1998). Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria. European Journal of Clinical Microbiology and Infectious Diseases 17, 193-5.